ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 250 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the firm’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $67.79, for a total value of $16,947.50. Following the sale, the vice president now directly owns 59,731 shares of the company’s stock, valued at $4,049,164.49. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Meredith Cook also recently made the following trade(s):

• On Tuesday, February 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $56.04, for a total value of $14,010.00.

ANI Pharmaceuticals Stock Performance

ANIP opened at $65.48 on Thursday. ANI Pharmaceuticals, Inc. has a 52-week low of $36.99 and a 52-week high of $70.81. The firm has a market capitalization of $1.38 billion, a PE ratio of 77.95 and a beta of 0.79. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.81 and a current ratio of 3.57. The business’s 50-day simple moving average is $64.60 and its 200 day simple moving average is $58.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The business had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Truist Financial lifted their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. HC Wainwright lifted their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Guggenheim lifted their target price on ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Finally, Capital One Financial began coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Buy” and an average price target of $80.00.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ANIP. China Universal Asset Management Co. Ltd. increased its position in ANI Pharmaceuticals by 93.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 248 shares during the last quarter. BluePath Capital Management LLC acquired a new position in ANI Pharmaceuticals during the third quarter worth approximately $34,000. Pacer Advisors Inc. acquired a new position in ANI Pharmaceuticals during the fourth quarter worth approximately $41,000. Point72 Asset Management L.P. increased its position in ANI Pharmaceuticals by 60.0% during the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 291 shares during the last quarter. Finally, Coppell Advisory Solutions LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth approximately $44,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.